Lipid changes due to fenofibrate treatment are not associated with changes in DNA methylation patterns in the GOLDN study

Lipid changes due to fenofibrate treatment are not associated with changes in DNA methylation patterns in the GOLDN study

Fenofibrate lowers triglycerides (TG) and raises high density lipoprotein cholesterol (HDLc) in dyslipidemic individuals. Several studies have shown genetic variability in lipid responses to fenofibrate treatment. It is, however, not known whether epigenetic patterns are also correlated with the cha...

Full description

Bibliographic Details
Main Authors:	Mithun eDas, Ryan eIrvin, Jin eSha, Stella eAslibekyan, Bertha eHidalgo, Rodney T Perry, Degui eZhi, Hemant K Tiwari, Devin eAbsher, Jose M Ordovas, Donna K Arnett
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2015-09-01
Series:	Frontiers in Genetics
Subjects:	DNA Methylation Fenofibrate cardiovascular disease Dyslipidemia Epigenetic changes Lipid lowering drug
Online Access:	http://journal.frontiersin.org/Journal/10.3389/fgene.2015.00304/full

Similar Items

Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study[S]
by: Mary K. Wojczynski, et al.
Published: (2010-11-01)

Comparison of efficacy and safety of choline fenofibrate (fenofibric acid) to micronized fenofibrate in patients of mixed dyslipidemia: A randomized, open-label, multicenter clinical trial in Indian population
by: Piyush Patel, et al.
Published: (2016-01-01)

Genomics of post-prandial lipidomic phenotypes in the Genetics of Lipid lowering Drugs and Diet Network (GOLDN) study.
by: Marguerite R Irvin, et al.
Published: (2014-01-01)

Development and validation of bioanalytical UHPLC-UV method for simultaneous analysis of unchanged fenofibrate and its metabolite fenofibric acid in rat plasma: Application to pharmacokinetics
by: Rayan G. Alamri, et al.
Published: (2017-01-01)

Comparison of efficacy and safety of fixed dose combination of rosuvastatin and choline fenofibrate to fixed dose combination of rosuvastatin and fenofibrate in patients of mixed dyslipidemia: A randomized, open-label, multicentre clinical trial in Indian population
by: Hanmant Barkate, et al.
Published: (2018-01-01)

Efficacy and Safety of Fenofibrate in Patients with Hyperuricemia
by: Irfan Zafar, et al.
Published: (2012-04-01)

Efficacy and Safety of Fenofibrate in Patients with Hyperuricemia
by: Irfan Zafar, et al.
Published: (2012-04-01)

Fenofibrate-induced renal dysfunction, yes or no?
by: Fatemeh Emami, et al.
Published: (2020-01-01)

The Therapeutic Effects of Fenofibrate on Blood Serum Lipid in Type II Diabetic Patients in El-beida, Libya
by: Yahya Saber E. Mansour, et al.
Published: (2019-09-01)

Fenofibrate-Induced Lichenoid Drug Eruption: A Rare Culprit
by: Fayeza Mohammed, et al.
Published: (2017-11-01)

Association of DNA Methylation at CPT1A Locus with Metabolic Syndrome in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) Study.
by: Mithun Das, et al.
Published: (2016-01-01)

Role of fenofibrate in multiple sclerosis
by: Ahmad A. Abulaban, et al.
Published: (2024-02-01)

Effect of Fenofibrate on Neonatal Hyperbilirubinemia: A Systematic Review and Meta-analysis
by: Nasrin Zamiri-Miandoab, et al.
Published: (2021-07-01)

Fenofibrate and Crataegus oxyacantha is an effectual combo for mixed dyslipidemia
by: Huda A Rasheed, et al.
Published: (2020-01-01)

Effects of fenofibrate in patients with type 2 diabetes mellitus complicated by diabetic neuropathy
by: Olga Nikolaevna Tkacheva, et al.
Published: (2010-03-01)

High-performance liquid chromatography and derivative spectrophotometry for simultaneous determination of pravastatin and fenofibrate in the dosage form
by: Hefnawy Mohamed M., et al.
Published: (2014-12-01)

Oral fenofibrate for hyperbilirubinemia in term neonates: A single-blind randomized controlled trial
by: Seyed Hossein Saadat, et al.
Published: (2023-01-01)

A comparative study on the effects of niacin plus atorvastatin with that of fenofibrate plus atorvastatin in dyslipidemia
by: Selim Ahmed, et al.
Published: (2008-04-01)

A comparative study on the effects of niacin plus atorvastatin with that of fenofibrate plus atorvastatin in dyslipidemia
by: Salim Ahmed, et al.
Published: (2008-06-01)

A comparative study of efficacy of atorvastatin alone and its combination with fenofibrate on lipid profile in type 2 diabetes mellitus patients with hyperlipidemia
by: Meenakshi Lella, et al.
Published: (2013-01-01)

A Rare Cause of Acute Renal Failure: Fenofibrate-Induced Rhabdomyolysis
by: Ferhat Icme, et al.
Published: (2013-08-01)

Indirect Neonatal Hyperbilirubinemia and the Role of Fenofibrate as an Adjuvant to Phototherapy
by: Salam K. Shabo, et al.
Published: (2023-07-01)

Anti-inflammatory role of fenofibrate in treating diseases
by: Lv Jin, et al.
Published: (2023-05-01)

Preparation and Evaluation of Lipid-Based Liquid Crystalline Formulation of Fenofibrate
by: Moloud Kazemi, et al.
Published: (2018-01-01)

High-Dose Fenofibrate Stimulates Multiple Cellular Stress Pathways in the Kidney of Old Rats
by: Agata Wrońska, et al.
Published: (2024-03-01)

Scale-up and optimization of fenofibrate-loaded fibers electrospun by corona-electrospinning
by: E. Bitay, et al.
Published: (2021-04-01)

Efficacy of Pemafibrate in Comparison to Fenofibrate and Bezafibrate on Triglyceride Levels and Liver, and Renal Functions in Patients With Hypertriglyceridemia and Type 2 Diabetes
by: Junko Oya, et al.
Published: (2023-11-01)

Detecting responses to treatment with fenofibrate in pedigrees
by: Svetlana Cherlin, et al.
Published: (2018-09-01)

Fenofibrate, a drug for COVID-19? All we need to know
by: Taimoor Hassan, et al.
Published: (2022-06-01)

The lipid-lowering drug fenofibrate combined with si-HOTAIR can effectively inhibit the proliferation of gliomas
by: Wei Zhu, et al.
Published: (2021-06-01)

Absence of a significant pharmacokinetic interaction between atorvastatin and fenofibrate: A randomized, crossover, study of a fixed-dose formulation in healthy Mexican subjects
by: Omar ePatiño-Rodríguez, et al.
Published: (2015-01-01)

Short-term effect of fenofibrate on C-reactive protein: A meta-analysis of randomized controlled trials
by: Ye Jiatao, et al.
Published: (2011-09-01)

Fenofibrate for the prevention of progression of non-proliferative diabetic retinopathy: review, consensus recommendations and guidance for clinical practice
by: Nor Fariza Ngah, et al.
Published: (2022-12-01)

Preferential Solvation of Fenofibrate in (Ethanol or Acetone) + Water Mixtures at 298.15 K
by: Abolghasem Jouyban, et al.
Published: (2017-08-01)

Pleiotropic effects of fenofibrate: focus on type 2 diabetes mellitus
by: Alexander Sergeevich Ametov, et al.
Published: (2014-12-01)

Fenofibrate Nanocrystals Embedded in Oral Strip-Films for Bioavailability Enhancement
by: Bhavesh D. Kevadiya, et al.
Published: (2018-02-01)

Genome- and CD4+ T-cell methylome-wide association study of circulating trimethylamine-N-oxide in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN)
by: Stella Aslibekyan, et al.
Published: (2017-06-01)

Long-Term Fenofibrate Treatment Stimulates the Phenotypic Microevolution of Prostate Cancer Cells In Vitro
by: Karolina W. Warzecha, et al.
Published: (2022-10-01)

Fenofibrate protects endothelial cells against the harmful effects of TNF-alpha
by: Westcott, Corli, et al.
Published: (2017-04-01)

Assessment of Adding Fenofibrate to Simvastatin on Exercise Test Findings in Patients with Dyslipidemia and Coronary Artery Disease
by: Reza Karbasi Afshar, et al.
Published: (2013-12-01)